Sep 10 |
Incannex announces strategic financing up to $60M
|
Sep 10 |
Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors
|
Sep 9 |
Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives
|
Aug 5 |
Incannex gets FDA okay for Phase 2 study of psilocybin drug
|
Aug 5 |
FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed
|
Jul 30 |
Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X
|
May 30 |
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
|
May 7 |
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
|
Apr 16 |
Incannex Healthcare Inc. Quarterly Update, Q1 2024
|